Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIGA-2050 in Hospitalized COVID-19 Patients
NCT04883138Phase 1Terminated
- Sponsor
- GigaGen Inc.
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GIGA-2050 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by GigaGen Inc. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of dose limiting toxicities and 2 more. Started May 2021; status: terminated.
02
Drugs
GIGA-2050
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04883138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883138.